Fairvalue-Calculator Fairvalue-Calculator
EN DE

Osang Healthcare Co (036220) Fair Value & Analysis

Healthcare · KR · Market cap 89.3B KRW

Price5,720 KRW
Fair Value5,381 KRW
Upside-5.9%
Quality95/100
Evidence: Medium Range 3,341 KRW – 6,995 KRW

Fair value as of: Jun 24, 2026

Analysis

Osang Healthcare Co (036220) currently trades at 5,720 KRW, while our model-based Fair Value estimate is 5,381 KRW — implying the stock looks roughly 5.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others. It also exports its products to approximately 110 countries worldwide. The company was formerly known as Infopia Co., Ltd. and changed its name to Osang Healthcare Co.,Ltd in April 2017. Osang Healthcare Co.,Ltd was founded in 1996 and is headquartered in Anyang-si, South Korea.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is Osang Healthcare Co (036220) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 5,381 KRW versus a price of 5,720 KRW — about −6% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 036220?
Our 21-model fair value for Osang Healthcare Co is 5,381 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 5,720 KRW.
What is the quality score of 036220?
Osang Healthcare Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.